Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity | Zendy

Jordan E. Lake | Zendy; Grace A. McComsey | Zendy; Todd Hulgan | Zendy; Christine Wanke | Zendy; Alexandra Mangili | Zendy; Sharon Walmsley | Zendy; Judith S. Currier | Zendy

Open Access

Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity

Author(s) -

Jordan E. Lake,

Grace A. McComsey,

Todd Hulgan,

Christine Wanke,

Alexandra Mangili,

Sharon Walmsley,

Judith S. Currier

Publication year - 2015

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofv059

Subject(s) - raltegravir , medicine , adipose tissue , integrase inhibitor , virology , protease inhibitor (pharmacology) , human immunodeficiency virus (hiv) , reverse transcriptase inhibitor , lipodystrophy , reverse transcriptase , antiretroviral therapy , viral load , polymerase chain reaction , biology , gene , biochemistry

Human immunodeficiency virus-infected women with central adiposity switched to raltegravir-based antiretroviral therapy immediately or after 24 weeks. No statistically significant changes in computed tomography-quantified visceral adipose tissue (VAT) or subcutaneous fat were observed, although 48 weeks of raltegravir was associated with a 6.4% VAT decline. Raltegravir for 24 weeks was associated with improvements in lipids.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research